Clinical details
| Months of follow-up after ITA initiation | ||||||||
| 0 (n=8) | 1 (n=8) | 3 (n=8) | 6 (n=8) | 9 (n=8) | 12 (n=8) | 18 (n=4) | 24 (n=3) | |
| VA mean, logMAR | 0.53 | 0.51 | 0.47 | 0.50 | 0.52 | 0.59 | 0.63 | 0.54 |
| VA change by ≥2 lines | ||||||||
| Improved, n (%) | NA | 0 | 0 | 0 | 2 (25) | 2 (25) | 0 | 0 |
| Stable, n (%) | NA | 8 (100) | 8 (100) | 7 (88) | 5 (62) | 4 (50) | 3 (75) | 2 (67) |
| Worse, n (%) | NA | 0 | 0 | 1 (12) | 1 (12) | 2 (25) | 1 (25) | 1 (33) |
| CFT, µm | 417 | 339 | 377 | 356 | 339 | 357 | 548 | 609 |
CFT, central foveal thickness; ITA, intravitreal triamcinolone acetonide; VA, visual acuity.